ロード中...
Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials
BACKGROUND: Patients undergoing chemotherapy are known to be at risk for infection from myelosuppression by cytotoxic agents (CTAs) or immunosuppressive effects from mTOR inhibitors. The infection risk of newly developed anticancer agents has not been fully evaluated. It remains unknown how T-cell a...
保存先:
| 出版年: | ESMO Open |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7174012/ https://ncbi.nlm.nih.gov/pubmed/32276948 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000653 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|